牛唐2021-03-31 09:44
$灿菲特生物制药(CANF)$ 的药物Piclidenoson和Namodenoson在现有的六份分销协议中,剩余的潜在里程碑付款高达约1.3亿美元,外加两位数的净销售额分成。$新泰医药(MDGL)$ $泰格医药(SZ300347)$查看全文
$灿菲特生物制药(CANF)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-03-19 AccNo: 0001178913-19-000864 Size: 96 KB 网页链接
$灿菲特生物制药(CANF)$ F-1/A [Amend] - Registration statement for certain foreign private issuers Filed: 2019-03-12 AccNo: 0001213900-19-003967 Size: 7 MB 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-03-11 AccNo: 0001213900-19-003918 Size: 11 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-03-04 AccNo: 0001213900-19-003517 Size: 9 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-02-25 AccNo: 0001213900-19-003051 Size: 35 KB 网页链接
$灿菲特生物制药(CANF)$ F-1 - Registration statement for certain foreign private issuers Filed: 2019-02-15 AccNo: 0001213900-19-002713 Size: 3 MB 网页链接
$灿菲特生物制药(CANF)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2019-02-04 AccNo: 0001193125-19-027003 Size: 129 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-02-04 AccNo: 0001213900-19-001603 Size: 25 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-01-30 AccNo: 0001213900-19-001402 Size: 23 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-02-01 AccNo: 0001213900-19-001577 Size: 10 MB 网页链接